SI2943507T1 - Inertni format - Google Patents

Inertni format

Info

Publication number
SI2943507T1
SI2943507T1 SI201431575T SI201431575T SI2943507T1 SI 2943507 T1 SI2943507 T1 SI 2943507T1 SI 201431575 T SI201431575 T SI 201431575T SI 201431575 T SI201431575 T SI 201431575T SI 2943507 T1 SI2943507 T1 SI 2943507T1
Authority
SI
Slovenia
Prior art keywords
inert
format
inert format
Prior art date
Application number
SI201431575T
Other languages
English (en)
Slovenian (sl)
Inventor
Aran Frank Labrijn
Joyce Meesters
Joost J. Neijssen
Den Brink Edward Norbert Van
Janine Schuurman
Paul Parren
Original Assignee
Genmab A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49881390&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2943507(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab A/S filed Critical Genmab A/S
Publication of SI2943507T1 publication Critical patent/SI2943507T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201431575T 2013-01-10 2014-01-09 Inertni format SI2943507T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361751045P 2013-01-10 2013-01-10
DKPA201300019 2013-01-10
PCT/EP2013/064330 WO2014006217A1 (en) 2012-07-06 2013-07-05 Dimeric protein with triple mutations
PCT/EP2014/050340 WO2014108483A1 (en) 2013-01-10 2014-01-09 Inert format
EP14700200.0A EP2943507B1 (en) 2013-01-10 2014-01-09 Inert format

Publications (1)

Publication Number Publication Date
SI2943507T1 true SI2943507T1 (sl) 2020-07-31

Family

ID=49881390

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431575T SI2943507T1 (sl) 2013-01-10 2014-01-09 Inertni format

Country Status (10)

Country Link
US (4) US11180572B2 (enExample)
EP (3) EP2869845B1 (enExample)
JP (3) JP6514103B2 (enExample)
CN (1) CN104736174B (enExample)
AU (4) AU2013285355A1 (enExample)
BR (1) BR112015000167B1 (enExample)
PL (1) PL2943507T3 (enExample)
SG (2) SG10201605703TA (enExample)
SI (1) SI2943507T1 (enExample)
WO (2) WO2014006217A1 (enExample)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
BRPI0817294A2 (pt) 2007-09-26 2015-03-17 Chugai Pharmaceutical Co Ltd Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
ES2740823T5 (en) 2008-01-15 2025-12-26 Univ Leland Stanford Junior Methods for manipulating phagocytosis mediated by cd47
WO2009091547A1 (en) 2008-01-15 2009-07-23 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP3056513A1 (en) 2008-04-11 2016-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP4477668A3 (en) * 2010-04-20 2025-03-19 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2647707T3 (pl) 2010-11-30 2019-02-28 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny wywołujący cytotoksyczność
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
AU2012245260B2 (en) 2011-04-22 2016-09-08 Aptevo Research And Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
PT2869845T (pt) * 2012-07-06 2019-12-09 Genmab Bv Proteína dimérica com mutações triplas
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE FC RII SPECIFIC FC ANTIBODY
TW202237660A (zh) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
WO2014145159A2 (en) * 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
AU2014238105B2 (en) 2013-03-15 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-CD47 agents
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
US20160068613A1 (en) 2013-04-29 2016-03-10 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
PL2992012T3 (pl) 2013-04-29 2019-12-31 F. Hoffmann-La Roche Ag Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania
ES2776706T3 (es) 2013-07-05 2020-07-31 Genmab As Anticuerpos contra CD3 humanizados o quiméricos
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
MX387180B (es) * 2014-01-15 2025-03-18 Hoffmann La Roche Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn).
EP3094647A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
EP3842455A1 (en) * 2014-01-15 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with improved protein a-binding
EP3114143B1 (en) 2014-03-05 2020-07-08 UCB Biopharma SRL Multimeric fc proteins
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
WO2015174439A1 (ja) 2014-05-13 2015-11-19 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
AU2015266880B2 (en) 2014-05-29 2019-03-21 Macrogenics, Inc. Tri-Specific Binding Molecules and methods of use thereof
MX2017005150A (es) * 2014-11-06 2017-08-08 Hoffmann La Roche Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
RU2714116C2 (ru) 2014-11-06 2020-02-11 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP4600372A3 (en) 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN114478792A (zh) * 2015-01-08 2022-05-13 根马布股份公司 针对cd3和cd20的双特异性抗体
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP3280736A1 (en) 2015-04-07 2018-02-14 F. Hoffmann-La Roche AG Antigen binding complex having agonistic activity and methods of use
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
US20180171017A1 (en) * 2015-06-05 2018-06-21 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
BR112018000696A2 (pt) * 2015-07-15 2018-09-18 Genmab As ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
CA3007031A1 (en) * 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
KR20180100412A (ko) 2016-01-10 2018-09-10 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
BR112018014668A2 (pt) * 2016-01-27 2018-12-11 Csl Behring Recombinant Facility Ag multímeros de fc de igg recombinante
EP3433281A1 (en) 2016-03-21 2019-01-30 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
SG11201808979UA (en) 2016-04-15 2018-11-29 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
KR102366813B1 (ko) 2016-05-27 2022-02-24 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
EA201990293A1 (ru) 2016-07-14 2019-07-31 Генмаб А/С Мультиспецифичные антитела против cd40 и cd137
CN109641048A (zh) * 2016-07-22 2019-04-16 格利克尼克股份有限公司 产生具有增强的Fc受体结合的经有序多聚化的免疫球蛋白Fc组合物的人蛋白片段的融合蛋白
KR102777127B1 (ko) 2016-08-02 2025-03-07 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
WO2018031400A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
TWI773686B (zh) 2016-09-13 2022-08-11 美商愛力根公司 非蛋白梭菌毒素組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
NZ792355A (en) 2016-10-11 2025-12-19 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
CA3041988A1 (en) 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
SG10201912560YA (en) 2016-12-07 2020-02-27 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
AU2018215673B2 (en) * 2017-02-06 2025-01-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
MA47449A (fr) * 2017-02-10 2019-12-18 Genmab Bv Variants polypeptidiques et ses utilisations
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
IL269645B2 (en) * 2017-03-31 2025-05-01 Genmab Holding B V Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
DK3618863T3 (da) 2017-05-01 2023-08-21 Agenus Inc Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
EP3630831B1 (en) 2017-05-25 2022-06-15 Bristol-Myers Squibb Company Antagonistic cd40 monoclonal antibodies and uses thereof
JP2020522254A (ja) 2017-05-31 2020-07-30 エルスター セラピューティクス， インコーポレイテッド 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
WO2018224609A1 (en) * 2017-06-07 2018-12-13 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
KR20240015159A (ko) * 2017-08-10 2024-02-02 그리폴스 다이어그노스틱 솔루션즈 인크. 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019047885A1 (en) * 2017-09-07 2019-03-14 Dingfu Biotarget Co., Ltd. IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN
CA3076482A1 (en) 2017-09-21 2019-03-28 Umc Utrecht Holding B.V. Anti-gd2 antibody for the treatment of neuroblastoma
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
AU2018347607B2 (en) 2017-10-14 2025-08-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
SG11202007390YA (en) 2018-02-08 2020-08-28 Genentech Inc Bispecific antigen-binding molecules and methods of use
CN111971298B (zh) 2018-03-12 2025-06-20 健玛保 抗体
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019175368A1 (en) * 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765494A4 (en) 2018-03-15 2022-03-23 Chugai Seiyaku Kabushiki Kaisha ANTI-DENGUE VIRUS ANTIBODIES WITH CROSS-REACTIVITY AGAINST ZIKA VIRUS AND METHODS OF USE
WO2019183362A1 (en) * 2018-03-21 2019-09-26 Dana-Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
CN112119097B (zh) * 2018-04-13 2021-10-15 艾菲默德有限责任公司 自然杀伤细胞接合抗体融合构建体
WO2019211472A1 (en) * 2018-05-03 2019-11-07 Genmab B.V. Antibody variant combinations and uses thereof
US12129298B2 (en) * 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
MA52951A (fr) 2018-06-22 2021-04-28 Genmab Holding B V Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
EP3820900A1 (en) * 2018-07-13 2021-05-19 Genmab A/S Variants of cd38 antibody and uses thereof
MA53123A (fr) * 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7709376B2 (ja) * 2018-10-23 2025-07-16 ブイオーアール バイオファーマ インコーポレーテッド Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
JP7737306B2 (ja) 2019-02-21 2025-09-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN114127113A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与钙网蛋白结合的多功能分子及其用途
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020168554A1 (zh) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 改造的Fc片段，包含其的抗体及其应用
US20220211767A1 (en) * 2019-04-27 2022-07-07 Figene, Llc Enhancement of fibroblast therapeutic activity by t cell modulation
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
US20230257479A1 (en) 2019-09-12 2023-08-17 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
CN112646041B (zh) * 2019-10-12 2023-11-10 上海睿智化学研究有限公司 包含抗体ch3域的异源二聚体及含其的抗体、融合蛋白
EP4055046A1 (en) * 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
EP4072584B1 (en) 2019-12-13 2026-01-28 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CA3165660A1 (en) * 2020-01-16 2021-07-22 Genmab A/S Formulations of cd38 antibodies and uses thereof
CA3167437A1 (en) * 2020-02-19 2021-08-26 Verena BRAND Modified fc regions
CN115485302A (zh) 2020-03-09 2022-12-16 百时美施贵宝公司 具有增强的激动剂活性的针对cd40的抗体
TW202200624A (zh) 2020-03-18 2022-01-01 丹麥商珍美寶股份有限公司 抗體
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN115916166A (zh) 2020-05-08 2023-04-04 健玛保 针对cd3和cd20的双特异性抗体
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
GB2616128A (en) 2020-08-26 2023-08-30 Marengo Therapeutics Inc Antibody molecules that bind to NKp30 and uses thereof
EP4204458A4 (en) 2020-08-26 2024-10-09 Marengo Therapeutics, Inc. METHODS FOR DETECTION OF TRBC1 OR TRBC2
US20230310599A1 (en) * 2020-09-02 2023-10-05 Genmab A/S Antibody therapy
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2023002544A (es) 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para tratar linfoma folicular.
JP2023542289A (ja) 2020-09-10 2023-10-06 ジェンマブ エー／エス 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
EP4210744A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
AU2021342342A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
BR112023005742A2 (pt) 2020-10-02 2023-05-02 Genmab As Anticorpo, composição, composição farmacêutica, método para tratar uma doença, ácido nucléico, vetor de expressão, célula, método para produzir um anticorpo, kit de partes, e, anticorpo anti-idiotípico
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
MX2023005132A (es) 2020-11-04 2023-05-25 Genentech Inc Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
US12516118B2 (en) 2020-11-04 2026-01-06 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
EP4305056A1 (en) * 2021-03-12 2024-01-17 Genmab A/S Non-activating antibody variants
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
US20240209116A1 (en) * 2021-04-28 2024-06-27 Ngm Biopharmaceuticals, Inc. Multimerization of binding molecules having an antibody constant region variant
MX2023012351A (es) 2021-05-07 2023-10-31 Genmab As Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3).
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
AR127743A1 (es) 2021-09-06 2024-02-28 Genmab Bv Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
EP4413039A1 (en) * 2021-10-08 2024-08-14 Genmab A/S Antibodies binding to cd30 and cd3
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
CA3247048A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE
US20250325643A1 (en) 2022-05-12 2025-10-23 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
JP2025518971A (ja) 2022-06-15 2025-06-19 アルジェニクス ビーブイ ｐＨ依存性ＨＳＡ結合分子及び使用方法
EP4582106A1 (en) * 2022-08-29 2025-07-09 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
TW202506178A (zh) 2023-04-05 2025-02-16 丹麥商珍美寶股份有限公司 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
AR133071A1 (es) 2023-06-30 2025-08-20 Genmab As ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025133694A1 (en) 2023-12-20 2025-06-26 argenx BV Fcrn/hsa-binding molecules and methods of use
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0486622B1 (en) 1989-08-09 1998-11-04 Rhomed, Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
WO1993002190A1 (en) 1991-07-15 1993-02-04 The Wellcome Foundation Limited Production of antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2717187B1 (fr) 1994-03-10 1996-05-31 Transgene Sa Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt.
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU3804397A (en) * 1996-06-14 1998-01-07 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
DK1150918T3 (da) 1999-02-03 2004-12-20 Biosante Pharmaceuticals Inc Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler
NZ514951A (en) 1999-04-15 2004-02-27 Crucell Holland B Recombinant protein production in a cultured human cell
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
NZ529788A (en) 2001-05-31 2003-12-19 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
DK1829972T3 (da) 2001-07-04 2010-09-13 Chromagenics Bv DNA-Sekvenser med anti-repressoraktivitet
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
ATE540978T1 (de) 2002-10-17 2012-01-15 Genmab As Humane monoklonale antikörper gegen cd20
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
ES2373947T3 (es) 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
KR101024443B1 (ko) 2003-01-07 2011-03-23 심포젠 에이/에스 재조합 폴리클로날 단백질의 제조 방법
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
EP2385069A3 (en) * 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
EP2374817B1 (en) * 2004-04-13 2017-09-06 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
ES2426816T3 (es) * 2004-08-04 2013-10-25 Mentrik Biotech, Llc Regiones Fc variantes
JP4487068B2 (ja) 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
CA2587617C (en) * 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
US20100104564A1 (en) 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
KR20080032026A (ko) 2005-05-09 2008-04-14 글리카트 바이오테크놀로지 아게 개질된 Ｆｃ 영역을 갖고 Ｆｃ 수용체에 변형된 결합을하는 항원 결합 분자
WO2007005612A2 (en) 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
RU2450020C2 (ru) 2006-01-05 2012-05-10 Дженентек, Инк. АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8940784B2 (en) 2006-02-02 2015-01-27 Syntarga B.V. Water-soluble CC-1065 analogs and their conjugates
WO2007106707A2 (en) * 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
WO2008114011A2 (en) 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
CA2685675C (en) * 2007-05-01 2016-02-16 Research Development Foundation Immunoglobulin fc libraries
ES2702087T3 (es) 2007-06-21 2019-02-27 Macrogenics Inc Diacuerpos covalentes y sus usos
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
US8680293B2 (en) 2007-08-01 2014-03-25 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
CA2712000A1 (en) * 2008-01-28 2009-08-06 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
SI2250279T1 (sl) 2008-02-08 2016-10-28 Medimmune, Llc Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda
CA2729095C (en) 2008-06-27 2018-12-04 Merus B.V. Method for producing a transgenic murine mammal
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
DE102008039957A1 (de) 2008-08-27 2010-03-04 Continental Automotive Gmbh Verfahren zur Ermittlung eines Unfallschwerekriteriums mittels eines Beschleunigungssignals und eines Körperschallsignals
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
JP5913980B2 (ja) * 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
RU2562232C2 (ru) 2008-11-03 2015-09-10 Синтарга Б.В. Новые аналоги сс-1065 и их конъюгаты
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
ES2986435T3 (es) 2008-12-19 2024-11-11 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2010132872A1 (en) 2009-05-15 2010-11-18 Novimmune S.A Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
MY152963A (en) 2009-06-26 2014-12-15 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
CN107337734A (zh) 2009-12-04 2017-11-10 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
NZ601111A (en) 2010-01-11 2014-07-25 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
EP4477668A3 (en) 2010-04-20 2025-03-19 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2807269A1 (en) 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US8785153B2 (en) 2011-02-23 2014-07-22 Hoffmann-La Roche, Inc. Antibodies against human IL33R and uses thereof
ES2668895T3 (es) 2011-03-16 2018-05-23 Amgen Inc. Variantes de Fc
WO2012143524A2 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
SMT201900239T1 (it) * 2011-05-21 2019-05-10 Macrogenics Inc Molecole di legame a cd3 in grado di legare cd3 umano e non umano
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
KR20200126007A (ko) 2012-04-20 2020-11-05 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
JP6377635B2 (ja) 2013-01-10 2018-08-22 ゲンマブ ビー．ブイ． ヒトＩｇＧ１Ｆｃ領域変異体およびその使用
ES2776706T3 (es) 2013-07-05 2020-07-31 Genmab As Anticuerpos contra CD3 humanizados o quiméricos
CN114478792A (zh) 2015-01-08 2022-05-13 根马布股份公司 针对cd3和cd20的双特异性抗体
BR112018000696A2 (pt) 2015-07-15 2018-09-18 Genmab As ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
EP3820900A1 (en) 2018-07-13 2021-05-19 Genmab A/S Variants of cd38 antibody and uses thereof

Also Published As

Publication number Publication date
US20230322947A1 (en) 2023-10-12
JP2022115955A (ja) 2022-08-09
EP2869845A1 (en) 2015-05-13
CN104736174B (zh) 2019-06-14
US20200332022A1 (en) 2020-10-22
US11180572B2 (en) 2021-11-23
JP2016508153A (ja) 2016-03-17
US20150337049A1 (en) 2015-11-26
BR112015000167A2 (pt) 2017-08-08
PL2943507T3 (pl) 2020-07-27
AU2022259785A1 (en) 2022-12-01
EP2943507B1 (en) 2020-02-26
AU2013285355A1 (en) 2015-01-29
JP2015524387A (ja) 2015-08-24
AU2022259785B2 (en) 2025-12-18
US20150175707A1 (en) 2015-06-25
EP2943507A1 (en) 2015-11-18
JP6604851B2 (ja) 2019-11-13
WO2014108483A1 (en) 2014-07-17
BR112015000167B1 (pt) 2021-11-23
WO2014006217A1 (en) 2014-01-09
WO2014006217A9 (en) 2015-02-26
EP2869845B1 (en) 2019-08-28
AU2018203510A1 (en) 2018-06-07
US11485796B2 (en) 2022-11-01
SG11201408646VA (en) 2015-01-29
US10590206B2 (en) 2020-03-17
SG10201605703TA (en) 2016-09-29
EP3738979A1 (en) 2020-11-18
CN104736174A (zh) 2015-06-24
AU2020202410A1 (en) 2020-04-30
JP6514103B2 (ja) 2019-05-15

Similar Documents

Publication Publication Date Title
SI2943507T1 (sl) Inertni format
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
PT2943507T (pt) Formato inerte
DK2946640T3 (da) Langmuir-probe
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
HUE036203T2 (hu) Spiro-oxazolonok
DE112014001252A5 (de) Aufbissschiene
DE102013107512B8 (de) Ohrhörer
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
DK3068356T3 (da) Ørestykke
FI10138U1 (fi) Kelkkateltta
ES1078715Y (es) Mosquitera
DE112014005422A5 (de) Friktionsfalschdrallaggregat